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Introduction
Desmopressin (dDAVP), a synthetic vasopressin analogue,
is a level 1, grade A treatment of monosymptomatic
enuresis nocturna (MNE).
Although evidence based results show superiority of
dDAVP above placebo, only 30 % of patients reach
complete continence.
Surrogate parameters predicting the dDAVP response
would be useful in individualizing therapy in children with
nocturnal enuresis. They have been an issue for debate
and research in the past decades.
Urinary osmolality in the morning was proposed by
several authors, but without convincing results.
Aim
The aim of this study was to explore the potential value of 
urinary osmolality in an early morning sample as a 
Method
surrogate parameter for dDAVP response.
Study population
45 children (> 5 years old) with MNE. ♂ 33/♀ 12
Severe enuresis = wet at least 5/7 nights.
Retrospective study
• 14 days diary for nocturnal enuresis episodes
and diuresis-volume
• Morning sample collection at time of waking up
• Subsequent treatment with dDAVP 2x200µg tablets in
Results
the evening for minimum 6 weeks
• 13/45 patients were full responder
• 15/45 patients partial responder
• Urinary osmolality did not correlate with dDAVP
response-rate (Fig.1)
• Nocturnal diuresis volume < 100% of expected bladder 
capacity for age 
correlated strongly with dDAVP resistance (Fig.2)
•Urinary osmolality-range was 675 to 1023 mosmol/l 
(Fig.3)
Conclusion: Urinary osmolality in the morning has no predicting value in 
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